» Authors » Rodrigo O Jacamo

Rodrigo O Jacamo

Explore the profile of Rodrigo O Jacamo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 558
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Nishida Y, Zhao R, Heese L, Akiyama H, Patel S, Jaeger A, et al.
Leukemia . 2021 Jun; 35(9):2469-2481. PMID: 34127794
Eukaryotic initiation factor 4A (eIF4A), the enzymatic core of the eIF4F complex essential for translation initiation, plays a key role in the oncogenic reprogramming of protein synthesis, and thus is...
2.
Zhang Q, Shi C, Han L, Jain N, Roberts K, Ma H, et al.
Oncotarget . 2018 Mar; 9(8):8027-8041. PMID: 29487712
Patients with cytokine receptor-like factor 2 rearranged (-re) subgroup Philadelphia chromosome-like B-cell acute lymphoblastic leukemia (Ph-like B-ALL) have a high relapse rate and poor clinical outcomes. -re Ph-like B-ALL is...
3.
Ishizawa J, Sugihara E, Kuninaka S, Mogushi K, Kojima K, Benton C, et al.
Blood . 2017 Feb; 129(14):1958-1968. PMID: 28143883
FZR1 (fizzy-related protein homolog; also known as CDH1 [cell division cycle 20 related 1]) functions in the cell cycle as a specific activator of anaphase-promoting complex or cyclosome ubiquitin ligase,...
4.
Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo R, et al.
Sci Signal . 2016 Feb; 9(415):ra17. PMID: 26884599
The clinical challenge posed by p53 abnormalities in hematological malignancies requires therapeutic strategies other than standard genotoxic chemotherapies. ONC201 is a first-in-class small molecule that activates p53-independent apoptosis, has a...
5.
Zhang W, Gao C, Konopleva M, Chen Y, Jacamo R, Borthakur G, et al.
Clin Cancer Res . 2014 Mar; 20(9):2363-74. PMID: 24619500
Purpose: FMS-like tyrosine kinase-3 (FLT3) internal tandem duplication (FLT3-ITD) mutations are common in patients with acute myeloid leukemia (AML). These patients regularly develop resistance to FLT3 inhibitors suggesting that targeted...
6.
Carter B, Mak P, Mak D, Shi Y, Qiu Y, Bogenberger J, et al.
J Natl Cancer Inst . 2014 Feb; 106(2):djt440. PMID: 24526787
Background: Acute myeloid leukemia (AML) therapy has limited long-term efficacy because patients frequently develop disease relapse because of the inability of standard chemotherapeutic agents to target AML stem/progenitor cells. Here,...
7.
Hofmann N, Ortner A, Jacamo R, Reinisch A, Schallmoser K, Rohban R, et al.
PLoS One . 2012 Sep; 7(9):e44468. PMID: 22970226
Despite insights into the molecular pathways regulating hypoxia-induced gene expression, it is not known which cell types accomplish oxygen sensing during neo-vasculogenesis. We have developed a humanized mouse model of...
8.
Battula V, Shi Y, Evans K, Wang R, Spaeth E, Jacamo R, et al.
J Clin Invest . 2012 May; 122(6):2066-78. PMID: 22585577
Cancer stem cells (CSCs) are a small subpopulation of cancer cells that have increased resistance to conventional therapies and are capable of establishing metastasis. However, only a few biomarkers of...
9.
Ahmed A, Lu Z, Jennings N, Etemadmoghadam D, Capalbo L, Jacamo R, et al.
Cancer Cell . 2010 Aug; 18(2):109-21. PMID: 20708153
Regulators of mitosis have been successfully targeted to enhance response to taxane chemotherapy. Here, we show that the salt inducible kinase 2 (SIK2) localizes at the centrosome, plays a key...
10.
Wu S, Jacamo R, Vong S, Rozengurt E
Cell Signal . 2006 Apr; 18(11):1932-40. PMID: 16574377
The calcium-dependent proline-rich tyrosine kinase Pyk2 is activated by tyrosine phosphorylation, associates with focal adhesion proteins, and has been linked to proliferative and migratory responses in a variety of mesenchymal...